Hematological Agents : Hematopoietic Agents
IEPRE1 “Eprex 2000 injection” 2000 IU/ml; 0.5 ml/syringe
適應症：治療與慢性腎臟功能失調有關的貧血症狀，或因此而需要輸血之患者；治療與癌症化學治療有關的貧血。
Usual dose:
Anemia of chronic renal failure: IV
Adult & Pediatric: 50-100 units/kg 3 times/wk; dose adjustments necessary to achieve or maintain hemoglobin levels within the recommended range of 10-12 g/dL.
Anemia, Due to chemotherapy:
Adult: SC 150 units/kg 3 times/wk for 8 wks, up to 300 units/kg 3 times/wk; discontinue after the completion of the chemotherapy course.
Pediatric: IV 600 units/kg qw up to a max. of 40,000 units.
Anemia – Zidovudine adverse reaction: IV/SC
Adult: 100 units/kg 3 times/wk for 8 wks; increase by 50-100 units/kg 3 times/wk up to a max. of 300 units/kg 3 times/wk.
Pediatric: 50-400 units/kg 2-3 times/wk.
Adverse effect:
Common: arthralgias, clotted access, headache, dizziness.
Serious: cerebral ischemia, cerebrovascular accident, hypertensive encephalopathy, seizure (cancer p’ts 1.2-3.2%, chronic renal failure p’ts 1.1% ), transient ischemic attack, pulmonary embolism, CHF, MI, tumor progression, immune hypersensitivity reaction, anemia, severe, deep venous thrombosis, porphyria, exacerbation, pure red cell aplasia.
健保使用規範：見darbepoetin Alfa。